WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B

 WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B

WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B

Shots:

  • Wuxi Vaccines to establish new manufacturing facility which includes drug substance manufacturing (DS), drug product manufacturing (DP), manufacture science and technology labs (MS&T) as well as quality control labs (QC)
  • The facility will develop and manufacture partner’s vaccine therapy for the global market. The new facility is expected to be operational in 2022
  • Additionally, in Nov’2019, Wuxi invests $240M to establish a new vaccine manufacturing facility in Ireland. Wuxi biologics will provide its global partners with a robust and premier-quality supply chain network to develop high-quality vaccines protecting humans globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bio Spectrum Asia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post